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Abstract
Background—Community-acquired pneumonia is a common cause of hospitalization among
African adults, and Streptococcus pneumoniae is assumed to be a frequent cause. Pneumococcal
conjugate vaccine is currently being introduced into childhood immunization programs in Africa.
The case for adult vaccination is dependent on the contribution of the pneumococcus to the
hospital pneumonia burden.
Methods—Pneumococcal diagnosis is complex because there is no gold standard, and culture
methods are invalidated by antibiotic use. We used latent class analysis to estimate the proportion
of pneumonia episodes caused by pneumococcus. Furthermore, we extended this methodology to
evaluate the effect of antimicrobial treatment on test accuracies and the prevalence of the disease.
The study combined data from five validation studies of pneumococcal diagnostic tests performed
on 281 Kenyan adults with pneumonia.
Results—The proportion of pneumonia episodes attributable to pneumococcus was 0.46 (95%
confidence interval = 0.36-0.57). Failure to account for the effect of antimicrobial exposure
underestimates this proportion as 0.32. A history of antibiotic exposure was a poor predictor of
anti-microbial activity in patients' urine. Blood culture sensitivity for pneumococcus was
estimated at 0.24 among patients with antibiotic exposure, and 0.75 among those without.
Conclusions—The large contribution of pneumococcus to adult pneumonia provides a strong
case for the investigation of pneumococcal vaccines in African adults.
Pneumonia ranks among the top three diagnoses in hospital admissions in sub-Saharan
Africa.1 In contrast to the USA,2 where most hospitalizations for pneumonia are among
children and the elderly, the typical African patient is a young, economically-productive
adult.3-5 These two observations suggest that a moderately-priced public-health-
intervention strategy against pneumonia is likely to be justifiable in Africa. For children in
the developing world there is considerable international momentum to prevent pneumonia
using conjugate vaccines against Haemophilus influenzae type b and Streptococcus
pneumoniae subsidized by the Global Alliance for Vaccines and Immunization.6,7 This
raises the prospect that adult vaccination may also become feasible in Africa. However, the
effectiveness of conjugate pneumococcal vaccine in adults against clinically-defined
pneumonia will depend critically on the proportion of hospitalized pneumonia cases that are
caused by S. pneumoniae.8
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S. pneumoniae is invariably found more frequently than any other pathogen in etiological
series of pneumonia in Africa.3,5,9 However, the clinical evidence is scarce and, as in the
USA and United Kingdom,10,11 the causal agent remains undiagnosed for a substantial
proportion of pneumonia cases. Diagnosis is hampered by the lack of a gold standard.
Although blood and lung-aspirate cultures are generally regarded as highly specific,12,13
they typically lack sensitivity, and antimicrobial treatment makes the evaluation of culture-
based diagnostic tests yet more complicated. Nonetheless, the common clinical treatments in
the developing world, (penicillin or ampicillin) reflects the clinical impression and
widespread belief that many of the pneumonia episodes without known cause are
pneumococcal.4,14-16
The objectives of this study were to define the proportion of episodes of community-
acquired pneumonia that are caused by S. pneumoniae, and describe the influence of
antimicrobial treatment on the accuracies of diagnostic tests. The study combined data from
five validation studies of diagnostic techniques for pneumococcal pneumonia.5,17-20
Because there is no gold standard for pneumococcal diagnosis, we applied latent class
analysis, a statistical method for estimating the unobserved latent disease status on the basis
of several imperfect test results.
Methods
Pneumonia patients
Cases consisted of 281 adults with acute community-acquired pneumonia consecutively
admitted to Coast Provincial General Hospital (Mombasa) and Kilifi District Hospital
(Kilifi, Kenya) between March 1994 and May 1996.5 Each case met all of the following
criteria: an acute illness of up to 14 days duration; at least 2 of the symptoms cough, sputum
production, breathlessness, pleuritic chest pain, hemoptysis or fever; evidence of
consolidation on posterio-anterior or lateral chest radiographs judged by the study physician
and later confirmed by a consultant radiologist5; no admission to hospital in the previous 14
days; and informed consent to participate to the study. Samples included blood, sputum, and
nasopharyngeal swabs for culture, lung-aspirate material from those in whom an aspirate
could be performed safely, urine, and acute sera. Convalescent sera were obtained in
survivors who attended a follow-up appointment. Mortality was 10%. The study was
approved by the ethical review committees of the Kenya Medical Research Institute and of
the London School of Hygiene and Tropical Medicine.
Microbiologic methods
Two aliquots of 10 ml of blood were drawn by separate venepunctures at presentation.
Blood and lung-aspirates were cultured in 40 ml of brain-heart infusion broth at 37°C in 5%
CO2 and sub-cultured to 5% horse blood agar and chocolate agar. S. pneumoniae was
identified by colonial morphology, sensitivity to optochin, and capsular serotyping by
Quellung reaction. Serotyping ambiguities were resolved by the Public Health Laboratory in
Oxford, UK.21 Homogenized sputum samples were cultured on blood agar with 5 mcg/mL
gentamicin, chocolate agar with 10,000U/ml bacitracin, and MacConkey agar. Cotton-
tipped, flexible, twisted-wire swab specimens were obtained from the posterior
nasopharynges of subjects and inoculated onto horse blood agar with 5 mcg of gentamicin/
mL. α-Hemolytic colonies were examined for optochin sensitivity and serotyped by the
Quellung reaction.
Serologic and molecular methods
Full methodologic details are contained in the cited references. In the urine antigen test,17
agglutination of latex particles sensitized with serogroup-specific rabbit antisera indicates
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the presence of capsular polysaccharide in urine.22 The capsular antigen detection assay was
conducted 10 times on each blinded urine sample to cover serogroups 1, 4, 5, 6, 7, 9, 12, 14,
19 and 22. An enzyme immunoassay was used to identify anti-pneumococcal immune
complexes.18 After precipitation of immune complexes from sera using polyethylene glycol
in sodium borate, an enzyme immunoassay was performed for antibodies to pneumolysin,
C-polysaccharide and 23-valent polysaccharide vaccine (Pneumovax, Merck). In an ELISA
for Anti-PsaA,19 antibodies binding to microtiter plates coated with pneumococcal surface
adhesin A (PsaA) were identified with an enzyme-conjugated mouse monoclonal antihuman
immunoglobulin G. A ratio rise in antibody concentration between acute and convalescent
sera of ≥ 2-fold was considered positive23 (anti-PsaA rise). Polymerase chain reaction
(PCR) for PsaA20 was performed as follows. A single pair of primers, 8229.p and 56496.n
(which define an 838-bp fragment of the PsaA gene of S. pneumoniae), were used in a
standard PCR on microbial DNA extracted from lung aspirate specimens.24 In addition, to
determine the HIV status of the patients, standard methods for HIV antibody positivity were
used.5
Bioassay for antimicrobial activity in urine
Urine samples were collected before administration of therapeutic antibiotics (n=248) and
the presence of antibiotics was inferred by the urine's capacity to inhibit the growth of a
fully-sensitive Staphylococcus aureus (NCTC 6571). Each patient was also questioned about
the use of antibiotics during the previous 2 days and during the preceding week.
Latent Class Analysis
Latent class analysis has been extensively applied in assessing accuracies of diagnostic tests
when the gold standard is not available.13,25-28 In latent class analysis it is assumed that
the observed association between the tests is fully explained by the unobserved (latent) class
variable, i.e. the true pneumococcal disease status (no/yes).
More formally, consider k tests (k ≥ 3) where each test Xi, i = 1, … , k can have two values:
1 if the test is positive for pneumococcus, and 0 if the test is negative. There are altogether
2k possible combinations of the test results. By utilizing the rule of total probability, these 2k
probabilities pr(X1 = x1, X2 = x2, … ,Xk = xk), xi = 0, 1, can be expressed in terms of the
latent class D as follows:
where pr(D = 1) denotes the proportion of S. pneumoniae among pneumonia patients, pr(Xi
= 1|D = 1) denote the sensitivities of individual tests, and pr(Xi = 0|D = 0) denote their
specificities. By assuming a multinomial distribution for the combination probabilities, the
parameters can be estimated by optimizing the criterion of maximum likelihood.
The appeal of latent class analysis is that it provides estimates for the unobserved quantities
of interest, namely the prevalence of the disease and the specificities and the sensitivities of
the tests. However, the assumptions underlying the methodology need to be carefully
scrutinized.
The conditional independence assumption
The standard latent class analysis model makes an essential assumption that the tests are
independent of each other, conditional on the pneumococcal disease status. When applied to
the analysis of diagnostic-test accuracies, this assumption has been justifiably questioned.29
For example, if the obtained sample has been contaminated with pneumococcus and two
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diagnostic tests (e.g. culture and PCR) are performed on the same sample, it is more likely
that both tests would indicate a false-positive result than if the tests were conditionally
independent.
Conditional dependence can be accounted for in latent class analysis. For example,
similarities between two diagnostic tests can be addressed by the direct-effects approach.28
Alternatively, an additional continuous or categorical latent variable can be imposed on the
conditional probabilities.26 However, care is needed in formulating these latent structures,
because misspecification of the dependence structure may result in even greater bias.27 A
practical alternative approach is to compare the fits of a model assuming conditional
independence and dependence between all possible pairs of tests using the likelihood ratio
test, and then select a set of diagnostic tests for which the conditional independence
assumption holds. Although this means that the accuracies of certain tests are left
unanalyzed, this is a particularly useful approach if the parameter of primary interest is the
prevalence of pneumococcal disease.
Treatment of missing data
A ubiquitous problem in the analysis of multiple diagnostic tests is that some observations
are missing from the study subjects. The simplest analytic approach is to exclude all subjects
without completely observed test results. However, this reduces the power of the analysis
and may introduce selection bias, i.e. subjects for whom all the test results are available may
not be a representative sample of the population.
When fitting models to all available data, two ignorable missing-data mechanisms can be
distinguished that have different implications on inference regarding the model
parameters30: missing completely at random (MCAR), and missing at random (MAR). If
the data are MCAR, it is assumed that those with missing samples originate from the same
population as those with complete observations. This assumption may be too strict for the
dataset in question. For example, some samples may be difficult to obtain from severely-ill
patients. Consequently, there may be differences in this subpopulation with regards to
pneumococcal disease burden. Under the assumption of MAR, the probability that a missing
test is positive can differ for those with partly-observed test combinations as long as this
probability is equal to the probability for those with complete data, conditional on the other
observed test results.
In our latent class analysis, we fitted models to the dataset of all patients, and assumed that
the unobserved test results were missing at random (MAR).30 Although there is no explicit
way to test the assumption of MAR, it is generally considered a tenable assumption in
multivariate analysis with missing data.31 Furthermore, if the data are erroneously assumed
to be MAR, this often has only minor impact on the estimates and standard errors.32
Accounting for antimicrobial exposure
Antimicrobial exposure reduces the sensitivity of culture-based tests.33 This causes complex
difficulties in the analysis of diagnostic accuracy in the absence of a gold standard. If the
patients taking antibiotics have a higher proportion of false-negative results for culture-
based tests, not only will the culture-based test parameters be biased, but those that are not
affected by antibiotics will also be biased because the culture-based tests fail to provide
support for the true-positives found by those other tests. A common analytic approach is to
exclude those with evidence of antimicrobial treatment. As with missing data, this reduces
power, and the sub-group not receiving antibiotics may not be a representative sample of the
population.
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We adopted two approaches to account for antibiotic exposure. In our primary analysis
(Model A), we coded culture results in the antibiotic-treated group as missing, and assumed
MAR. That is, the probabilities of positive culture results are assumed to be equal in both
the antibiotic and non-antibiotic groups, conditional on the results of the non-culture-based
tests. Secondly, we conducted an analysis (Model B) in which all culture results were
included as observed, but the specificities and the sensitivities of the culture tests were
allowed to vary across the two antibiotic groups. This approach was taken because
antimicrobial treatment is common, and the accuracies of the culture-based tests during
antimicrobial exposure may themselves be of interest. To determine the magnitude of bias,
we also fitted a model that took no account of antimicrobial exposure (Model C).
Results
Exploratory analysis results
In the preliminary analyses, none of the immunocomplex enzyme immunoassays were
associated with blood and lung-aspirate cultures, which are generally regarded as highly
specific. This accords with earlier findings that these immunoassays provide little or no
predictive value in the pneumococcal pneumonia diagnosis.34 The leftmost column of Table
1 reports the summary of the available tests performed for 281 pneumonia patients after
excluding these immunoassay results.
Results on antimicrobial exposure
We determined the antimicrobial exposure of patients on the basis of the urinary
antimicrobial assay. Based on this gold standard, the sensitivity of self-reported antibiotic
use in the last 2 days was 0.51 (69/135) and specificity was 0.78 (88/113). This discrepancy
between self-reports and urine tests is probably explained by the use of antimalarials, which
are a common first choice of treatment for fever, and some of which have antibiotic
properties. Of patients who reported taking no antibiotics in the last two days, 57% had
evidence of antimicrobial activity in urine. All of these patients reported taking no
antibiotics for the whole of the preceding week. The rightmost columns of Table 1 report the
percentages of positive results of seven pneumococcal tests in groups with and without
urinary evidence of antimicrobial treatment. Of urine samples from 281 patients, 135 were
positive for antimicrobial activity and 113 were negative; urine was not obtained from 33
patients before inpatient antibiotic therapy started. The results are consistent with previous
findings that antimicrobial treatment eradicates positive bacterial results when using culture-
based tests.33
Latent class analysis results
The dataset for the primary analysis and model diagnosis contained all seven tests listed in
Table 1. However, out of 281 patients, only the culture results of those not under
antimicrobial treatment were used (113 patients). The model fit to the data was significantly
better when assuming conditional dependence between lung-aspirate culture and PCR
(likelihood ratio test χ2 = 7.8; P = 0.02 with 2 df), and between sputum culture and
nasopharyngeal swab culture (likelihood ratio test χ2 = 8.4; P = 0.02 with 2 df). Both are
plausible findings, considering the shared location from which the specimens were obtained.
Since lung-aspirate culture is regarded as highly specific, and nasopharyngeal swab culture
prevalence was considerably higher than that of sputum culture, we omitted lung-aspirate
PCR and sputum culture, leaving five tests in the final analysis. Consequently, since culture
results of patients under antimicrobial treatment were coded missing for this analysis, five
patients were missing all test results. Thus the final number of patients analyzed was 276.
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When no parameter constraints were applied, the specificities of both blood and lung-
aspirate cultures were estimated as 97%. Because the literature suggests that these tests are
in fact 100% specific,12,13 we decided to constrain these two specificities to 100%. The fit
of the constrained model did not differ significantly from that of the unconstrained model
(likelihood ratio test χ2 = 2.5; P = 0.28 with 2 df).
Table 2 reports the estimates of Model A with 95% confidence intervals (CI's). The
goodness-of-fit test, conditional on the MAR assumption,35 indicated that Model A fitted
the data well (χ2 = 18.5 with 22 df; P = 0.68). The estimated proportion of S. pneumoniae
among inpatients with pneumonia is 0.46 (95% CI=0.36-0.57).
The estimates of the secondary analysis (Model B), where the sensitivity and specificity
estimates for the culture tests were permitted to vary between antibiotic-exposure groups,
are shown in Table 3. For patients under antimicrobial treatment, the sensitivities of culture
tests are considerably reduced. To illustrate the magnitude of bias, Table 3 also reports the
estimates of the Model C where the antibiotic exposure is completely unaccounted for.
(Detailed summaries of Model B and C are available with the online version of this article).
According to the predicted 276 individual probabilities using Model A, the average
probability of S. pneumoniae in those exposed to antibiotics (48 %) was slightly higher than
in non-exposed (42 %). The probability of pneumococcal etiology did not differ in those
with a fatal outcome.
We also conducted an analysis similar to Model B, in which we allowed the test accuracies
to differ between HIV-infected (n=147) and HIV non-infected (n=134); we found no
differences (likelihood ratio test against Model A; χ2 = 8.7 with 8 df; P = 0.37). The
prevalence estimate, when fitted to a subgroup of HIV-infected only, was 43 % (95%
CI=31-55). For HIV non-infected, the model did not identify.
Discussion
Our primary objective of the study was not to evaluate assays for individual diagnosis but
rather to estimate the contribution of S. pneumoniae to the burden of community-acquired
pneumonia as accurately as possible. We used a study that included a comprehensive set of
laboratory diagnostics together with a latent class analysis that accounted for the bias due to
antimicrobial exposure. Among Kenyan adult patients with pneumonia leading to
hospitalization, we estimate that 46 % of episodes are attributable to pneumococcus.
We found no differences in either pneumococcal prevalence or the test accuracies between
HIV-infected and HIV non-infected patients. Although HIV status is an important factor in
most health outcomes, our results suggest that HIV is not associated with the ability of the
tests to detect pneumococcus as the causative pathogen for pneumonia. In contrast,
antimicrobial exposure is a highly-important factor when estimating pneumococcal
prevalence on the basis of imperfect diagnostic test results.
Of our three models, Model A provides the most accurate estimate of the prevalence of S.
pneumoniae among patients with pneumonia by eliminating the bias inherent in using
culture results from patients who have taken antibiotics. In Model C, where no account is
taken of antimicrobial treatment, the prevalence of S. pneumoniae is underestimated by
almost 15% as compared with Model A. It is important to note that the test accuracies
derived by Model A correspond to a population in which no antimicrobial treatment is used.
Because in practice, such a population is highly improbable, we also conducted an analysis
to evaluate the test accuracies under antimicrobial treatment (Model B).
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As expected, cultures of blood and lung aspirates were highly-specific tests for determining
pneumococcal involvement. The sensitivity of blood culture (75%) was markedly higher
than in a previous report13 (36%), where subjects under antimicrobial treatment were
excluded from analysis. However, our analysis showed that treatment by antimicrobials
strongly reduces blood-culture sensitivity (24% when exposed to antibiotics), and that the
determination of antimicrobial exposure can be considerably biased without biomarker
information. Focusing only on those not treated with antibiotics may also introduce selection
bias.
A rapid immunochromatographic test (ICT) for C-polysaccharide antigen detection in urine
has shown sensitivities in the range of 70-80% and specificities of 90-100%.36 Conversely,
a study in which latent class analysis was applied,13 estimated that the sensitivity and
specificity of the ICT urine test were 77% and 71%, respectively. The detection of capsular
antigen has also shown high specificity (98%) in a separate validation study,17 whereas the
specificity estimate (83%) from our latent class analysis was less impressive. In validation
studies, either imperfect gold standards or other patient groups are used, whereas in latent
class analysis, the estimates are based on the concept of true disease. It must be noted,
however, that the true disease status in latent class analysis is inherently unverifiabe.
A two-fold increase in Anti-PsaA IgG was the most sensitive diagnostic test (88%).
Although the specificity (83 %) would not be high enough for the purposes of a vaccine
trial, the test may be useful in providing an approximate estimate of the prevalence of
pneumococcus in pneumonia patients, especially as the assay is unaffected by antimicrobial
treatment. As our study has shown, accounting for the effect of antimicrobial exposure is
challenging, both in measurement and in analysis.
Pneumococcal colonization is a prerequisite for pneumococcal pneumonia. However,
coincidental carriage during a pneumonia episode is also relatively common and may lead to
false positives by other diagnostic tests. Our analysis aimed to separate these two processes,
both of which originate from pneumococcal colonization. Our view is that the most coherent
approach for this separation is through a joint analysis of all test results using latent class
analysis. As an indirect proof of the validity of Model A, we derived the positive predictive
value of nasopharyngeal swab culture, which was 0.59. Given that pneumococcus had a
prevalence of 46% in pneumonia cases, the nasopharyngeal swab culture of pneumococcus
adds little to the etiologic diagnosis.
Among diagnostic studies of pneumonia, a positive etiologic test is consistently found
among only about two-thirds of patients.5,10,11 It has been suggested that a large
proportion of cases that remain undiagnosed are in fact caused by pneumococcus.5
Unfortunately, this suggested verification bias is generally intractable, because none of the
currently available tests is sensitive enough to corroborate the hypothesis. It is surprising
that recent advances in laboratory science have not been translated into epidemiologic gains
in the diagnosis of pneumococcal pneumonia. Polymerase chain reaction (PCR) for
pneumococcal gene targets, which may detect numbers of organisms too low to grow in
culture37, and detect non-viable organisms after treatment with antibiotics33, has shown
sensitivities in clinical studies of only 29-69%38-40 when compared with blood cultures.
However, despite all the difficulties and uncertainties in pneumonia diagnosis, our analyses
provide at least a lower limit of the disease burden caused by S. pneumoniae.
Among children in the Gambia, a 9-valent pneumococcal conjugate vaccine has been shown
to have an efficacy of 50% against invasive pneumococcal disease, and an efficacy of 37%
against radiologically-confirmed pneumonia7. The Global Alliance for Vaccine and
Immunization has signaled its intention to accelerate introduction of conjugate
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pneumococcal vaccine for children in the developing world. As radiologically-confirmed
pneumonia is a common cause of adult morbidity and mortality in sub-Saharan Africa, it is
pertinent to ask whether adults would not likewise benefit from immunization. The efficacy
of the vaccine is unknown in adults, but our estimate that almost half of inpatient episodes of
pneumonia in Kenyan adults are caused by S. pneumoniae provides a strong incentive to
investigate it.
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Table 2
Estimates of a Latent Class Model A fitted to a dataset of diagnostic test results of 276 Kenyan adults with
pneumonia
Parameter Estimate 95 % CI
Percentage of S. pneumoniae 46 (36-57)
Specificity (%)
 NPS culture 50 (36-65)
 lung-aspirate culture 100
 blood culture 100
 urine antigen 82 (75-90)
 Anti-PsaA rise 83 (68-98)
Sensitivity (%)
 NPS culture 82 (70-94)
 lung-aspirate culture 55 (39-71)
 blood culture 75 (59-91)
 urine antigen 50 (39-61)
 Anti-PsaA rise 88 (79-97)
In Model A the culture results of those under antimicrobial exposure are coded missing
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Table 3
Comparison of parameter estimates of Latent Class Models fitted to a dataset of diagnostic test results of 276
Kenyan adults with pneumonia.
Parameter Model A Model B Model C
no antibiotics antibiotics
Percentage of S. pneumoniae 46 39 32
Specificity (%)
 NPS culture 50 48 95 75
 lung-aspirate culture 100 100 100 100
 blood culture 100 100 100 100
 urine antigen 82 79 75
 Anti-PsaA rise 83 72 65
Sensitivity (%)
 NPS culture 82 82 61 77
 lung-aspirate culture 55 58 35 59
 blood culture 75 80 24 62
 urine antigen 50 51 49
 Anti-PsaA rise 88 83 84
Model A is the one reported in Table 2. In Model B different sensitivities and specificities are allowed for culture tests in the two antimicrobial
exposure groups. In Model C antimicrobial exposure is unaccounted for.
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